Oryzon participates in a R&D European consortium in Parkinson’s disease
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
Oryzon will launch its first product onto the market
Oryzon to Present at CTAD 2010 Conference in Toulouse, France.
Dr. Marta Palicio, Scientific Business Developer at Oryzon, has been invited to participate in the roundtable Biomarkers and translational medicine: new paradigms for personalized medicine
06/07/2011
